Proteoglycans in prostate cancer

Nature Reviews Urology

Volumn 9, Issue 4, 2012, Pages 196-206

  Edwards, Iris J ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIGLYCAN; CHEMOKINE; CORE PROTEIN; DECORIN; GLYCOSAMINOGLYCAN; GROWTH FACTOR; LUMICAN; PERLECAN; PROTEOGLYCAN; SCLEROPROTEIN; SONIC HEDGEHOG PROTEIN; SYNDECAN 1; SYNDECAN 2; SYNDECAN 3; TRANSFORMING GROWTH FACTOR BETA RECEPTOR 3;

APOPTOSIS; CANCER GROWTH; CELL ADHESION; CELL COMMUNICATION; CELL FUNCTION; CELL GROWTH; CELL MOTILITY; ENZYME ACTIVITY; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; UPREGULATION;

ANIMALS; CELL MOVEMENT; HUMANS; MALE; PROSTATIC NEOPLASMS; PROTEOGLYCANS; SIGNAL TRANSDUCTION;

EID: 84859631941     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2012.19     Document Type: Review

References (130)

1. Theocharis, A. D., Skandalis, S. S., Tzanakakis, G. N. & Karamanos, N. K. Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277, 3904-3923 (2010).
2. Iozzo, R. V. & Schaefer, L. Proteoglycans in health and disease: novel regulatory signaling mechanisms evoked by the small leucine-rich proteoglycans. FEBS J. 277, 3864-3875 (2010).
3. Manon-Jensen, T., Itoh, Y. & Couchman, J. R. Proteoglycans in health and disease: the multiple roles of syndecan shedding. FEBS J. 277, 3876-3889 (2010).
4. Friedl, A. Proteoglycans: master modulators of paracrine fibroblast-carcinoma cell interactions. Semin. Cell Dev. Biol. 21, 66-71 (2010).
5. Kjellen, L. & Lindahl, U. Proteoglycans: structures and interactions. Annu. Rev. Biochem. 60, 443-475 (1991).
6. Lindahl, U., Kusche-Gullberg, M. & Kjellen, L. Regulated diversity of heparan sulfate. J. Biol. Chem. 273, 24979-24982 (1998).
7. Esko, J. D. & Lindahl, U. Molecular diversity of heparan sulfate. J. Clin. Invest. 108, 169-173 (2001).
8. Gallagher, J. T. Heparan sulfate: growth control with a restricted sequence menu. J. Clin. Invest. 108, 357-361 (2001).
9. Iozzo, R. V. Matrix proteoglycans: from molecular design to cellular function. Annu. Rev. Biochem. 67, 609-652 (1998).
10. Bernfield, M. et al. Functions of cell surface heparan sulfate proteoglycans. Annu. Rev. Biochem. 68, 729-777 (1999).
11. Thomson, A. A. & Cunha, G. R. Prostatic growth and development are regulated by FGF10. Development 126, 3693-3701 (1999).
12. Mohammadi, M., Olsen, S. K. & Ibrahimi, O. A. Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev. 16, 107-137 (2005).
13. Buresh, R. A. et al. Sulfatase 1 is an inhibitor of ductal morphogenesis with sexually dimorphic expression in the urogenital sinus. Endocrinology 151, 3420-3431 (2010).
14. Podlasek, C. A., Barnett, D. H., Clemens, J. Q., Bak, P. M. & Bushman, W. Prostate development requires Sonic hedgehog expressed by the urogenital sinus epithelium. Dev. Biol. 209, 28-39 (1999).
15. Datta, S., Pierce, M. & Datta, M. W. Perlecan signaling: helping hedgehog stimulate prostate cancer growth. Int. J. Biochem. Cell Biol. 38, 1855-1861 (2006).
16. Sakko, A. J. et al. Changes in steroid receptors and proteoglycan expression in the guinea pig prostate stroma during puberty and hormone manipulation. Prostate 67, 288-300 (2007).
17. Kolset, S. O. & Tveit, H. Serglycin--structure and biology. Cell. Mol. Life Sci. 65, 1073-1085 (2008).
18. Niemann, C. U., Kjeldsen, L., Ralfkiaer, E., Jensen, M. K. & Borregaard, N. Serglycin proteoglycan in hematologic malignancies: a marker of acute myeloid leukemia. Leukemia 21, 2406-2410 (2007).
19. Meen, A. J. et al. Serglycin is a major proteoglycan in polarized human endothelial cells and is implicated in the secretion of the chemokine GROalpha/CXCL1. J. Biol. Chem. 286, 2636-2647 (2011).
20. Li, X. J. et al. Serglycin is a theranostic target in nasopharyngeal carcinoma that promotes metastasis. Cancer Res. 71, 3162-3172 (2011).
21. Theocharis, A. D. et al. Serglycin constitutively secreted by myeloma plasma cells is a potent inhibitor of bone mineralization in vitro. J. Biol. Chem. 281, 35116-35128 (2006).
22. Cohen, R. J., Holland, J. W., Redmond, S. L., McNeal, J. E. & Dawkins, H. J. Identification of the glycosaminoglycan keratan sulfate in the prostatic secretory cell. Prostate 44, 204-209 (2000).
23. Holland, J. W., Meehan, K. L., Redmond, S. L. & Dawkins, H. J. Purification of the keratan sulfate proteoglycan expressed in prostatic secretory cells and its identification as lumican. Prostate 59, 252-259 (2004).
24. Ricciardelli, C., Sakko, A. J., Ween, M. P., Russell, D. L. & Horsfall, D. J. The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev. 28, 233-245 (2009).
25. Wight, T. N. Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 14, 617-623 (2002).
26. Wu, Y. J., La Pierre, D. P., Wu, J., Yee, A. J. & Yang, B. B. The interaction of versican with its binding partners. Cell Res. 15, 483-494 (2005).
27. Hirose, J., Kawashima, H., Yoshie, O., Tashiro, K. & Miyasaka, M. Versican interacts with chemokines and modulates cellular responses. J. Biol. Chem. 276, 5228-5234 (2001).
28. Dours-Zimmermann, M. T. & Zimmermann, D. R. A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J. Biol. Chem. 269, 32992-32998 (1994).
29. Sakko, A. J. et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 63, 4786-4791 (2003).
30. Ricciardelli, C. et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin. Cancer Res. 4, 963-971 (1998).
31. Ricciardelli, C. et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J. Biol. Chem. 282, 10814-10825 (2007).
32. Read, J. T. et al. Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J. Biol. Chem. 282, 31954-31963 (2007).
33. Sakko, A. J. et al. Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res. 61, 926-930 (2001).
34. Cross, N. A. et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63, 269-275 (2005).
35. Sandy, J. D. et al. Versican V1 proteolysis in human aorta in vivo occurs at the Glu441-Ala442 bond, a site that is cleaved by recombinant ADAMTS-1 and ADAMTS-4. J. Biol. Chem. 276, 13372-13378 (2001).
36. Somerville, R. P. et al. Characterization of ADAMTS-9 and ADAMTS-20 as a distinct ADAMTS subfamily related to Caenorhabditis elegans GON-1. J. Biol. Chem. 278, 9503-9513 (2003).
37. Schaefer, L. & Iozzo, R. V. Biological functions of the small leucine-rich proteoglycans: from genetics to signal transduction. J. Biol. Chem. 283, 21305-21309 (2008).
38. Scott, P. G. et al. Crystal structure of the dimeric protein core of decorin, the archetypal small leucine-rich repeat proteoglycan. Proc. Natl Acad. Sci. USA 101, 15633-15638 (2004).
39. Schaefer, L. & Schaefer, R. M. Proteoglycans: from structural compounds to signaling molecules. Cell Tissue Res. 339, 237-246 (2010).
40. Weber, I. T., Harrison, R. W. & Iozzo, R. V. Model structure of decorin and implications for collagen fibrillogenesis. J. Biol. Chem. 271, 31767-31770 (1996).
41. Neame, P. J., Kay, C. J., McQuillan, D. J., Beales, M. P. & Hassell, J. R. Independent modulation of collagen fibrillogenesis by decorin and lumican. Cell. Mol. Life Sci. 57, 859-863 (2000).
42. Svensson, L. et al. Fibromodulin-null mice have abnormal collagen fibrils, tissue organization, and altered lumican deposition in tendon. J. Biol. Chem. 274, 9636-9647 (1999).
43. Yamaguchi, Y., Mann, D. M. & Ruoslahti, E. Negative regulation of transforming growth factor-beta by the proteoglycan decorin. Nature 346, 281-284 (1990).
44. Moscatello, D. K. et al. Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. J. Clin. Invest. 101, 406-412 (1998).
45. Iozzo, R. V., Moscatello, D. K., McQuillan, D. J. & Eichstetter, I. Decorin is a biological ligand for the epidermal growth factor receptor. J. Biol. Chem. 274, 4489-4492 (1999).
46. Santra, M., Eichstetter, I. & Iozzo, R. V. An anti-oncogenic role for decorin. Downregulation of ErbB2 leads to growth suppression and cytodifferentiation of mammary carcinoma cells. J. Biol. Chem. 275, 35153-35161 (2000).
47. Csordas, G. et al. Sustained downregulation of the epidermal growth factor receptor by decorin. A mechanism for controlling tumor growth in vivo. J. Biol. Chem. 275, 32879-32887 (2000).
48. Goldoni, S. et al. Decorin is a novel antagonistic ligand of the Met receptor. J. Cell Biol. 185, 743-754 (2009).
49. Schonherr, E., Sunderkotter, C., Iozzo, R. V. & Schaefer, L. Decorin, a novel player in the insulin-like growth factor system. J. Biol. Chem. 280, 15767-15772 (2005).
50. Mauviel, A., Santra, M., Chen, Y. Q., Uitto, J. & Iozzo, R. V. Transcriptional regulation of decorin gene expression. Induction by quiescence and repression by tumor necrosis factor-alpha. J. Biol. Chem. 270, 11692-11700 (1995).
51. Santra, M. et al. Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. J. Clin. Invest. 100, 149-157 (1997).
52. Reed, C. C., Gauldie, J. & Iozzo, R. V. Suppression of tumorigenicity by adenovirus-mediated gene transfer of decorin. Oncogene 21, 3688-3695 (2002).
53. Reed, C. C. et al. Decorin prevents metastatic spreading of breast cancer. Oncogene 24, 1104-1110 (2005).
54. Biglari, A. et al. Effects of ectopic decorin in modulating intracranial glioma progression in vivo, in a rat syngeneic model. Cancer Gene Ther. 11, 721-732 (2004).
55. Tralhao, J. G. et al. In vivo selective and distant killing of cancer cells using adenovirus-mediated decorin gene transfer. FASEB J. 17, 464-466 (2003).
56. Banerjee, A. G. et al. Expression of biomarkers modulating prostate cancer angiogenesis: differential expression of annexin II in prostate carcinomas from India and USA. Mol. Cancer 2, 34 (2003).
57. Coulson-Thomas, V. J. et al. Fibroblast and prostate tumor cell cross-talk: fibroblast differentiation, TGF-beta, and extracellular matrix downregulation. Exp. Cell Res. 316, 3207-3226 (2010).
58. Wang, S. et al. Prostate-specific deletion of the murine Pten tumor suppressor gene leads to metastatic prostate cancer. Cancer Cell 4, 209-221 (2003).
59. Hu, Y. et al. Decorin suppresses prostate tumor growth through inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11, 1042-1053 (2009).
60. Mimeault, M. & Batra, S. K. Recent advances on multiple tumorigenic cascades involved in prostatic cancer progression and targeting therapies. Carcinogenesis 27, 1-22 (2006).
61. Fassan, M. et al. Mitostatin is downregulated in human prostate cancer and suppresses the invasive phenotype of prostate cancer cells. PLoS ONE 6, e19771 (2011).
62. Vecchione, A. et al. MITOSTATIN, a putative tumor suppressor on chromosome 12q24.1, is downregulated in human bladder and breast cancer. Oncogene 28, 257-269 (2009).
63. Chen, N. et al. A secreted isoform of ErbB3 promotes osteonectin expression in bone and enhances the invasiveness of prostate cancer cells. Cancer Res. 67, 6544-6548 (2007).
64. Chen, X. D., Fisher, L. W., Robey, P. G. & Young, M. F. The small leucine-rich proteoglycan biglycan modulates BMP-4-induced osteoblast differentiation. FASEB J. 18, 948-958 (2004).
65. Wang, J., Levenson, A. S. & Satcher, R. L. Jr. Identification of a unique set of genes altered during cell-cell contact in an in vitro model of prostate cancer bone metastasis. Int. J. Mol. Med. 17, 849-856 (2006).
66. Chakravarti, S. et al. Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican. J. Cell Biol. 141, 1277-1286 (1998).
67. Kao, W. W. & Liu, C. Y. Roles of lumican and keratocan on corneal transparency. Glycoconj. J. 19, 275-285 (2002).
68. Leygue, E. et al. Expression of lumican in human breast carcinoma. Cancer Res. 58, 1348-1352 (1998).
69. Matsuda, Y. et al. Expression and roles of lumican in lung adenocarcinoma and squamous cell carcinoma. Int. J. Oncol. 33, 1177-1185 (2008).
70. Ishiwata, T. et al. Role of lumican in cancer cells and adjacent stromal tissues in human pancreatic cancer. Oncol. Rep. 18, 537-543 (2007).
71. Brezillon, S. et al. Expression of lumican, a small leucine-rich proteoglycan with antitumor activity, in human malignant melanoma. Clin. Exp. Dermatol. 32, 405-416 (2007).
72. D'Onofrio, M. F. et al. Identification of beta1 integrin as mediator of melanoma cell adhesion to lumican. Biochem. Biophys. Res. Commun. 365, 266-272 (2008).
73. Brezillon, S. et al. Lumican inhibits B16F1 melanoma cell lung metastasis. J. Physiol. Pharmacol. 60 (Suppl. 4), 15-22 (2009).
74. Vij, N., Roberts, L., Joyce, S. & Chakravarti, S. Lumican suppresses cell proliferation and aids Fas-Fas ligand mediated apoptosis: implications in the cornea. Exp. Eye Res. 78, 957-971 (2004).
75. Lee, S., Bowrin, K., Hamad, A. R. & Chakravarti, S. Extracellular matrix lumican deposited on the surface of neutrophils promotes migration by binding to beta2 integrin. J. Biol. Chem. 284, 23662-23669 (2009).
76. Leygue, E. et al. Lumican and decorin are differentially expressed in human breast carcinoma. J. Pathol. 192, 313-320 (2000).
77. Luo, J. et al. Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis. Prostate 51, 189-200 (2002).
78. Iozzo, R. V., Zoeller, J. J. & Nystrom, A. Basement membrane proteoglycans: modulators Par Excellence of cancer growth and angiogenesis. Mol. Cells 27, 503-513 (2009).
79. Iozzo, R. V. & San Antonio, J. D. Heparan sulfate proteoglycans: heavy hitters in the angiogenesis arena. J. Clin. Invest. 108, 349-355 (2001).
80. Murdoch, A. D., Liu, B., Schwarting, R., Tuan, R. S. & Iozzo, R. V. Widespread expression of perlecan proteoglycan in basement membranes and extracellular matrices of human tissues as detected by a novel monoclonal antibody against domain III and by in situ hybridization. J. Histochem. Cytochem. 42, 239-249 (1994).
81. Iozzo, R. V., Cohen, I. R., Grassel, S. & Murdoch, A. D. The biology of perlecan: the multifaceted heparan sulfate proteoglycan of basement membranes and pericellular matrices. Biochem. J. 302 (Pt 3), 625-639 (1994).
82. Savore, C. et al. Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo. Clin. Exp. Metastasis 22, 377-390 (2005).
83. Datta, M. W. et al. Perlecan, a candidate gene for the CAPB locus, regulates prostate cancer cell growth via the Sonic Hedgehog pathway. Mol. Cancer 5, 9 (2006).
84. Karhadkar, S. S. et al. Hedgehog signaling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004).
85. Gatza, C. E., Oh, S. Y. & Blobe, G. C. Roles for the type III TGF-beta receptor in human cancer. Cell Signal 22, 1163-1174 (2010).
86. Bernfield, M. et al. Biology of the syndecans: a family of transmembrane heparan sulfate proteoglycans. Annu. Rev. Cell Biol. 8, 365-393 (1992).
87. Kim, C. W., Goldberger, O. A., Gallo, R. L. & Bernfield, M. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol. Biol. Cell 5, 797-805 (1994).
88. Liu, W. et al. Heparan sulfate proteoglycans as adhesive and anti-invasive molecules. Syndecans and glypican have distinct functions. J. Biol. Chem. 273, 22825-22832 (1998).
89. Woods, A., Oh, E. S. & Couchman, J. R. Syndecan proteoglycans and cell adhesion. Matrix Biol. 17, 477-483 (1998).
90. Liebersbach, B. F. & Sanderson, R. D. Expression of syndecan-1 inhibits cell invasion into type I collagen. J. Biol. Chem. 269, 20013-20019 (1994).
91. Dhodapkar, M. V. et al. Syndecan-1 is a multifunctional regulator of myeloma pathobiology: control of tumor cell survival, growth, and bone cell differentiation. Blood 91, 2679-2688 (1998).
92. Endo, K. et al. Cleavage of syndecan-1 by membrane type matrix metalloproteinase-1 stimulates cell migration. J. Biol. Chem. 278, 40764-40770 (2003).
93. Kato, M. et al. Physiological degradation converts the soluble syndecan-1 ectodomain from an inhibitor to a potent activator of FGF-2. Nat. Med. 4, 691-697 (1998).
94. Mali, M., Elenius, K., Miettinen, H. M. & Jalkanen, M. Inhibition of basic fibroblast growth factor-induced growth promotion by overexpression of syndecan-1. J. Biol. Chem. 268, 24215-24222 (1993).
95. Mali, M., Andtfolk, H., Miettinen, H. M. & Jalkanen, M. Suppression of tumor cell growth by syndecan-1 ectodomain. J. Biol. Chem. 269, 27795-27798 (1994).
96. Nikolova, V. et al. Differential roles for membrane-bound and soluble syndecan-1 (CD138) in breast cancer progression. Carcinogenesis 30, 397-407 (2009).
97. Inki, P., Joensuu, H., Grenman, R., Klemi, P. & Jalkanen, M. Association between syndecan-1 expression and clinical outcome in squamous cell carcinoma of the head and neck. Br. J. Cancer 70, 319-323 (1994).
98. Matsumoto, A. et al. Reduced expression of syndecan-1 in human hepatocellular carcinoma with high metastatic potential. Int. J. Cancer 74, 482-491 (1997).
99. Nackaerts, K. et al. Heparan sulfate proteoglycan expression in human lung-cancer cells. Int. J. Cancer 74, 335-345 (1997).
100. Pulkkinen, J. O., Penttinen, M., Jalkanen, M., Klemi, P. & Grenman, R. Syndecan-1: a new prognostic marker in laryngeal cancer. Acta Otolaryngol. 117, 312-315 (1997).
101. Anttonen, A., Kajanti, M., Heikkila, P., Jalkanen, M. & Joensuu, H. Syndecan-1 expression has prognostic significance in head and neck carcinoma. Br. J. Cancer 79, 558-564 (1999).
102. Numa, F. et al. Syndecan-1 expression in cancer of the uterine cervix: association with lymph node metastasis. Int. J. Oncol. 20, 39-43 (2002).
103. Loussouarn, D. et al. Prognostic impact of syndecan-1 expression in invasive ductal breast carcinomas. Br. J. Cancer 98, 1993-1998 (2008).
104. Leppa, S., Mali, M., Miettinen, H. M. & Jalkanen, M. Syndecan expression regulates cell morphology and growth of mouse mammary epithelial tumor cells. Proc. Natl Acad. Sci. USA 89, 932-936 (1992).
105. Sun, H., Berquin, I. M., Owens, R. T., O'Flaherty, J. T. & Edwards, I. J. Peroxisome proliferator-activated receptor gamma-mediated upregulation of syndecan-1 by n-3 fatty acids promotes apoptosis of human breast cancer cells. Cancer Res. 68, 2912-2919 (2008).
106. Hu, Y. et al. Syndecan-1-dependent suppression of PDK1/Akt/bad signaling by docosahexaenoic acid induces apoptosis in prostate cancer. Neoplasia 12, 826-836 (2010).
107. Conejo, J. R. et al. Syndecan-1 expression is upregulated in pancreatic but not in other gastrointestinal cancers. Int. J. Cancer 88, 12-20 (2000).
108. Barbareschi, M. et al. High syndecan-1 expression in breast carcinoma is related to an aggressive phenotype and to poorer prognosis. Cancer 98, 474-483 (2003).
109. Davies, E. J. et al. Distribution and clinical significance of heparan sulfate proteoglycans in ovarian cancer. Clin. Cancer Res. 10, 5178-5186 (2004).
110. Watanabe, A. et al. Expression of syndecans, a heparan sulfate proteoglycan, in malignant gliomas: participation of nuclear factor-kappaB in upregulation of syndecan-1 expression. J. Neurooncol. 77, 25-32 (2006).
111. Choi, D. S. et al. Syndecan-1, a key regulator of cell viability in endometrial cancer. Int. J. Cancer 121, 741-750 (2007).
112. Mennerich, D. et al. Shift of syndecan-1 expression from epithelial to stromal cells during progression of solid tumors. Eur. J. Cancer 40, 1373-1382 (2004).
113. Stanley, M. J., Stanley, M. W., Sanderson, R. D. & Zera, R. Syndecan-1 expression is induced in the stroma of infiltrating breast carcinoma. Am. J. Clin. Pathol. 112, 377-383 (1999).
114. Maeda, T., Alexander, C. M. & Friedl, A. Induction of syndecan-1 expression in stromal fibroblasts promotes proliferation of human breast cancer cells. Cancer Res. 64, 612-621 (2004).
115. Maeda, T., Desouky, J. & Friedl, A. Syndecan-1 expression by stromal fibroblasts promotes breast carcinoma growth in vivo and stimulates tumor angiogenesis. Oncogene 25, 1408-1412 (2006).
116. Su, G., Blaine, S. A., Qiao, D. & Friedl, A. Shedding of syndecan-1 by stromal fibroblasts stimulates human breast cancer cell proliferation via FGF2 activation. J. Biol. Chem. 282, 14906-14915 (2007).
117. Sanderson, R. D. et al. Enzymatic remodeling of heparan sulfate proteoglycans within the tumor microenvironment: growth regulation and the prospect of new cancer therapies. J. Cell Biochem. 96, 897-905 (2005).
118. Chen, D. et al. Syndecan-1 expression in locally invasive and metastatic prostate cancer. Urology 63, 402-407 (2004).
119. Kiviniemi, J. et al. Altered expression of syndecan-1 in prostate cancer. APMIS 112, 89-97 (2004).
120. Brimo, F., Vollmer, R. T., Friszt, M., Corcos, J. & Bismar, T. A. Syndecan-1 expression in prostate cancer and its value as biomarker for disease progression. BJU Int. 106, 418-423 (2010).
121. Shariat, S. F. et al. Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int. 101, 232-237 (2008).
122. Zellweger, T. et al. Expression patterns of potential therapeutic targets in prostate cancer. Int. J. Cancer 113, 619-628 (2005).
123. Lerner, I. et al. Function of heparanase in prostate tumorigenesis: potential for therapy. Clin. Cancer Res. 14, 668-676 (2008).
124. Edwards, I. J. et al. In vivo and in vitro regulation of syndecan 1 in prostate cells by N.-3 polyunsaturated fatty acids. J. Biol. Chem. 283, 18441-18449 (2008).
125. Danielpour, D. Functions and regulation of transforming growth factor-beta (TGF-beta) in the prostate. Eur. J. Cancer 41, 846-857 (2005).
126. Sharifi, N., Hurt, E. M., Kawasaki, B. T. & Farrar, W. L. TGFBR3 loss and consequences in prostate cancer. Prostate 67, 301-311 (2007).
127. Ajiboye, S., Sissung, T. M., Sharifi, N. & Figg, W. D. More than an accessory: implications of type III transforming growth factor-beta receptor loss in prostate cancer. BJU Int. 105, 913-916 (2010).
128. Turley, R. S. et al. The type III transforming growth factor-beta receptor as a novel tumor suppressor gene in prostate cancer. Cancer Res. 67, 1090-1098 (2007).
129. Lopez-Casillas, F., Payne, H. M., Andres, J. L. & Massague, J. Betaglycan can act as a dual modulator of TGF-beta access to signaling receptors: mapping of ligand binding and GAG attachment sites. J. Cell Biol. 124, 557-568 (1994).
130. Bandyopadhyay, A. et al. Systemic administration of a soluble betaglycan suppresses tumor growth, angiogenesis, and matrix metalloproteinase-9 expression in a human xenograft model of prostate cancer. Prostate 63, 81-90 (2005).